APO Research
Talk to an analyst

APO RESEARCH · REPORT

Severe Acute Respiratory Syndrome (SARS) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025181 pages

Choose your research edition.

Industry ResearchSevere Acute Respiratory Syndrome (SARS) Therapeutics Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Severe Acute Respiratory Syndrome (SARS) Therapeutics include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Severe Acute Respiratory Syndrome (SARS) Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Severe Acute Respiratory Syndrome (SARS) Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Severe Acute Respiratory Syndrome (SARS) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Company

CEL-SCI Corporation

GeneCure LLC

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Type

LCA-60

INO-4500

FDX-000

D-3252

CEL-1000

Others

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Application

Research Center

Hospital

Clinic

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Severe Acute Respiratory Syndrome (SARS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Acute Respiratory Syndrome (SARS) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Severe Acute Respiratory Syndrome (SARS) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Severe Acute Respiratory Syndrome (SARS) Therapeutics industry.

Chapter 3: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Severe Acute Respiratory Syndrome (SARS) Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of LCA-60 Table 3. Key Players of INO-4500 Table 4. Key Players of FDX-000 Table 3. Key Players of D-3252 Table 4. Key Players of CEL-1000 Table 5. Key Players of Others Table 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 7. Key Players of Research Center Table 8. Key Players of Hospital Table 9. Key Players of Clinic Table 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2021-2026) Table 13. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2027-2032) Table 15. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends Table 16. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers Table 17. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges Table 18. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints Table 19. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Company (2021-2026) Table 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Company Head Office and Area Served Table 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company, Product Type & Application Table 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2027-2032) Table 37. CEL-SCI Corporation Company Information Table 38. CEL-SCI Corporation Business Overview Table 39. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 41. CEL-SCI Corporation Recent Development Table 42. GeneCure LLC Company Information Table 43. GeneCure LLC Business Overview Table 44. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 46. GeneCure LLC Recent Development Table 47. Humabs BioMed SA Company Information Table 48. Humabs BioMed SA Business Overview Table 49. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 51. Humabs BioMed SA Recent Development Table 52. Inovio Pharmaceuticals, Inc. Company Information Table 53. Inovio Pharmaceuticals, Inc. Business Overview Table 54. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 56. Inovio Pharmaceuticals, Inc. Recent Development Table 57. Nanotherapeutics, Inc. Company Information Table 58. Nanotherapeutics, Inc. Business Overview Table 59. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 61. Nanotherapeutics, Inc. Recent Development Table 62. Novavax, Inc. Company Information Table 63. Novavax, Inc. Business Overview Table 64. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 66. Novavax, Inc. Recent Development Table 67. Phelix Therapeutics, LLC Company Information Table 68. Phelix Therapeutics, LLC Business Overview Table 69. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 71. Phelix Therapeutics, LLC Recent Development Table 72. Protein Sciences Corporation Company Information Table 73. Protein Sciences Corporation Business Overview Table 74. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 76. Protein Sciences Corporation Recent Development Table 77. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 78. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 79. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 80. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 81. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) Table 83. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032) Table 84. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 85. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 86. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 87. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 88. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) Table 90. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032) Table 91. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 92. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 93. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 94. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 95. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 96. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 97. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 98. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 99. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) Table 101. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032) Table 102. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 103. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 104. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 105. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 106. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) Table 108. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Image Figure 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. LCA-60 Image Figure 5. INO-4500 Image Figure 6. FDX-000 Image Figure 7. D-3252 Image Figure 8. CEL-1000 Image Figure 9. Others Image Figure 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 11. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application: 2025 VS 2032 Figure 12. Research Center Image Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 17. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Players in 2025 Figure 20. Global Top 5 and 10 Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2021-2032) Figure 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2021-2032) Figure 26. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 27. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032) Figure 28. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032) Figure 29. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 30. United States Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 31. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 32. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 33. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 34. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032) Figure 35. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032) Figure 36. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 37. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 41. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 43. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 44. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032) Figure 45. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032) Figure 46. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 47. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032) Figure 48. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032) Figure 49. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 50. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 54. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 55. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 60. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. South Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 65. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 66. Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 67. Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • LCA-60
  • INO-4500
  • FDX-000
  • D-3252
  • CEL-1000
  • Others
Applications
  • Research Center
  • Hospital
  • Clinic
Companies covered
  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 LCA-60
  5. 1.2.3 INO-4500
  6. 1.2.4 FDX-000
  7. 1.2.5 D-3252
  8. 1.2.6 CEL-1000
  9. 1.2.7 Others
  10. 1.3 Market Analysis by Application
  11. 1.3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  12. 1.3.2 Research Center
  13. 1.3.3 Hospital
  14. 1.3.4 Clinic
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Growth Trends by Region
  17. 1.5.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2026)
  19. 1.5.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
  1. 2.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
  2. 2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers
  3. 2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company, Product Type & Application
  5. 3.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Severe Acute Respiratory Syndrome (SARS) Therapeutics Tier 1, Tier 2, and Tier 3
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type
  1. 4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2032)
5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Application
  1. 5.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 CEL-SCI Corporation
  2. 6.1.1 CEL-SCI Corporation Company Information
  3. 6.1.2 CEL-SCI Corporation Business Overview
  4. 6.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  6. 6.1.5 CEL-SCI Corporation Recent Developments
  7. 6.2 GeneCure LLC
  8. 6.2.1 GeneCure LLC Company Information
  9. 6.2.2 GeneCure LLC Business Overview
  10. 6.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  12. 6.2.5 GeneCure LLC Recent Developments
  13. 6.3 Humabs BioMed SA
  14. 6.3.1 Humabs BioMed SA Company Information
  15. 6.3.2 Humabs BioMed SA Business Overview
  16. 6.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  18. 6.3.5 Humabs BioMed SA Recent Developments
  19. 6.4 Inovio Pharmaceuticals, Inc.
  20. 6.4.1 Inovio Pharmaceuticals, Inc. Company Information
  21. 6.4.2 Inovio Pharmaceuticals, Inc. Business Overview
  22. 6.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  24. 6.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
  25. 6.5 Nanotherapeutics, Inc.
  26. 6.5.1 Nanotherapeutics, Inc. Company Information
  27. 6.5.2 Nanotherapeutics, Inc. Business Overview
  28. 6.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  30. 6.5.5 Nanotherapeutics, Inc. Recent Developments
  31. 6.6 Novavax, Inc.
  32. 6.6.1 Novavax, Inc. Company Information
  33. 6.6.2 Novavax, Inc. Business Overview
  34. 6.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  36. 6.6.5 Novavax, Inc. Recent Developments
  37. 6.7 Phelix Therapeutics, LLC
  38. 6.7.1 Phelix Therapeutics, LLC Company Information
  39. 6.7.2 Phelix Therapeutics, LLC Business Overview
  40. 6.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  42. 6.7.5 Phelix Therapeutics, LLC Recent Developments
  43. 6.8 Protein Sciences Corporation
  44. 6.8.1 Protein Sciences Corporation Company Information
  45. 6.8.2 Protein Sciences Corporation Business Overview
  46. 6.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  48. 6.8.5 Protein Sciences Corporation Recent Developments
7 North America
  1. 7.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  2. 7.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  3. 7.2.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  7. 7.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country
  11. 7.4.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  3. 8.2.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  7. 8.3.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country
  11. 8.4.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  2. 9.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  3. 9.2.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  7. 9.3.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  3. 10.2.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  7. 10.3.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country
  11. 10.4.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst